Matches in SemOpenAlex for { <https://semopenalex.org/work/W2014509406> ?p ?o ?g. }
- W2014509406 endingPage "50" @default.
- W2014509406 startingPage "41" @default.
- W2014509406 abstract "Tumor-initiating cells (TICs) often survive therapy and give rise to second-line tumors. We tested the plausibility of sphere cultures as models of TICs. Microarray data and microRNA data analysis confirmed the validity of spheres as models of TICs for breast and prostate cancer as well as mesothelioma cell lines. Microarray data analysis revealed the Trp pathway as the only pathway upregulated significantly in all types of studied TICs, with increased levels of indoleamine-2,3-dioxygenase-1 (IDO1), the rate-limiting enzyme of Trp metabolism along the kynurenine pathway. All types of TICs also expressed higher levels of the Trp uptake system consisting of CD98 and LAT1 with functional consequences. IDO1 expression was regulated via both transcriptional and posttranscriptional mechanisms, depending on the cancer type. Serial transplantation of TICs in mice resulted in gradually increased IDO1. Mitocans, represented by α-tocopheryl succinate and mitochondrially targeted vitamin E succinate (MitoVES), suppressed IDO1 in TICs. MitoVES suppressed IDO1 in TICs with functional mitochondrial complex II, involving transcriptional and posttranscriptional mechanisms. IDO1 increase and its suppression by VE analogues were replicated in TICs from primary human glioblastomas. Our work indicates that IDO1 is increased in TICs and that mitocans suppress the protein." @default.
- W2014509406 created "2016-06-24" @default.
- W2014509406 creator A5006075298 @default.
- W2014509406 creator A5007374771 @default.
- W2014509406 creator A5012894625 @default.
- W2014509406 creator A5017770625 @default.
- W2014509406 creator A5025167197 @default.
- W2014509406 creator A5027399159 @default.
- W2014509406 creator A5030829136 @default.
- W2014509406 creator A5035925084 @default.
- W2014509406 creator A5044908880 @default.
- W2014509406 creator A5045789498 @default.
- W2014509406 creator A5045794004 @default.
- W2014509406 creator A5060128303 @default.
- W2014509406 creator A5067401201 @default.
- W2014509406 creator A5081205047 @default.
- W2014509406 creator A5082131007 @default.
- W2014509406 creator A5082750710 @default.
- W2014509406 creator A5085243063 @default.
- W2014509406 creator A5086206120 @default.
- W2014509406 creator A5089883387 @default.
- W2014509406 creator A5090375198 @default.
- W2014509406 creator A5090819945 @default.
- W2014509406 creator A5091720138 @default.
- W2014509406 date "2014-02-01" @default.
- W2014509406 modified "2023-10-18" @default.
- W2014509406 title "Indoleamine-2,3-dioxygenase elevated in tumor-initiating cells is suppressed by mitocans" @default.
- W2014509406 cites W1495741014 @default.
- W2014509406 cites W1927805387 @default.
- W2014509406 cites W1964081206 @default.
- W2014509406 cites W1964895626 @default.
- W2014509406 cites W1966912859 @default.
- W2014509406 cites W1984484036 @default.
- W2014509406 cites W1986199117 @default.
- W2014509406 cites W1990412352 @default.
- W2014509406 cites W1997626619 @default.
- W2014509406 cites W1998149716 @default.
- W2014509406 cites W1999601075 @default.
- W2014509406 cites W2001627351 @default.
- W2014509406 cites W2001951399 @default.
- W2014509406 cites W2013563294 @default.
- W2014509406 cites W2015526806 @default.
- W2014509406 cites W2015991580 @default.
- W2014509406 cites W2017342990 @default.
- W2014509406 cites W2020131167 @default.
- W2014509406 cites W2026144912 @default.
- W2014509406 cites W2026379260 @default.
- W2014509406 cites W2036881708 @default.
- W2014509406 cites W2046972425 @default.
- W2014509406 cites W2050779943 @default.
- W2014509406 cites W2051055358 @default.
- W2014509406 cites W2058834701 @default.
- W2014509406 cites W2060551076 @default.
- W2014509406 cites W2068424305 @default.
- W2014509406 cites W2069106402 @default.
- W2014509406 cites W2072078248 @default.
- W2014509406 cites W2073302269 @default.
- W2014509406 cites W2086946343 @default.
- W2014509406 cites W2087801719 @default.
- W2014509406 cites W2090410108 @default.
- W2014509406 cites W2094530868 @default.
- W2014509406 cites W2095174045 @default.
- W2014509406 cites W2100626569 @default.
- W2014509406 cites W2100914972 @default.
- W2014509406 cites W2101163066 @default.
- W2014509406 cites W2101385118 @default.
- W2014509406 cites W2101433429 @default.
- W2014509406 cites W2106195342 @default.
- W2014509406 cites W2108143410 @default.
- W2014509406 cites W2114570899 @default.
- W2014509406 cites W2115226431 @default.
- W2014509406 cites W2117692326 @default.
- W2014509406 cites W2119739306 @default.
- W2014509406 cites W2121626779 @default.
- W2014509406 cites W2122012981 @default.
- W2014509406 cites W2124292154 @default.
- W2014509406 cites W2127617517 @default.
- W2014509406 cites W2130410032 @default.
- W2014509406 cites W2131774025 @default.
- W2014509406 cites W2147807172 @default.
- W2014509406 cites W2147955536 @default.
- W2014509406 cites W2148219135 @default.
- W2014509406 cites W2154648782 @default.
- W2014509406 cites W2164216268 @default.
- W2014509406 cites W2165948908 @default.
- W2014509406 cites W2167414381 @default.
- W2014509406 cites W4244935210 @default.
- W2014509406 doi "https://doi.org/10.1016/j.freeradbiomed.2013.10.003" @default.
- W2014509406 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24145120" @default.
- W2014509406 hasPublicationYear "2014" @default.
- W2014509406 type Work @default.
- W2014509406 sameAs 2014509406 @default.
- W2014509406 citedByCount "25" @default.
- W2014509406 countsByYear W20145094062015 @default.
- W2014509406 countsByYear W20145094062016 @default.
- W2014509406 countsByYear W20145094062017 @default.
- W2014509406 countsByYear W20145094062018 @default.
- W2014509406 countsByYear W20145094062019 @default.